Zydus has announced biological therapy ZRC-3308, used to treat mild COVID-19. The pharmaceutical company now seeks DCGI (Drugs Controller General of India) nod to undertake clinical trials for monoclonal antibodies cocktail that can neutralise Covid infection.
In a statement, Dr Sharvil Patel, Managing Director of Cadila Healthcare Limited, said they believe that ‘biological therapy’ ZRC-3308 – ‘a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs)’, has the potential to address concerns abut the progression of the disease.
In a press release, the pharmaceutical company said the ZRC-3308 is designed to have a “long half-life providing protection for a long period of time” and has “reduced immune-effector to minimize potential tissue-damaging side effects of virus neutralising monoclonal antibodies thereby providing a safer product.”